All In Biotech

Drug Trial Radar · NCT05174637

A Study of FDA018-ADC in Patients With Advanced Solid Tumors

A PhaseⅠStudy to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of FDA018-ADC in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Oct 22, 2021

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Jan 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of FDA018-ADC in patients with advanced/metastatic solid tumors.

Conditions

  • Advanced/ Metastatic Solid Tumors

Interventions

  • FDA018-ADCDrug

    Subjects will receive an intravenous infusion of FDA018-ADC until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The dose limiting toxicity ( DLT)Time frame: From first dose to the end of Cycle 1, up to 35 days.
  2. The maximum tolerated dose (MTD)Time frame: From first dose to the end of Cycle 1, up to 35 days.
  3. Adverse EventsTime frame: From subject randomization up to 60 months
  4. Objective Response Rate (ORR) according to RECIST 1.1Time frame: From subject randomization up to 60 months.
  5. Recommended phase II dose (RP2D)Time frame: From subject randomization up to 60 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.